| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | dabrafenib | CTRPv2 | pan-cancer | AAC | -0.014 | 0.8 |
| mRNA | Cisplatin | GDSC1000 | pan-cancer | AAC | 0.01 | 0.8 |
| mRNA | BRD-K13999467 | CTRPv2 | pan-cancer | AAC | -0.011 | 0.8 |
| mRNA | BRD-K99006945 | CTRPv2 | pan-cancer | AAC | -0.016 | 0.8 |
| mRNA | RG-108 | CTRPv2 | pan-cancer | AAC | -0.011 | 0.8 |
| mRNA | RO4929097 | CTRPv2 | pan-cancer | AAC | 0.016 | 0.8 |
| mRNA | TAE684 | CTRPv2 | pan-cancer | AAC | -0.011 | 0.8 |
| mRNA | Oxaliplatin | CTRPv2 | pan-cancer | AAC | -0.0097 | 0.8 |
| mRNA | ISOX:bortezomib (250:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.01 | 0.8 |
| mRNA | canertinib | CTRPv2 | pan-cancer | AAC | 0.011 | 0.8 |